Microcap Ledger Mustang BIO, Inc. $MBIO
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Waltham, MA
- Fiscal year end
- December 31
What the company doesAI summary of filing
Mustang Bio is a clinical-stage biopharmaceutical company developing therapies for solid tumors, particularly malignant brain cancers. The company licenses technologies from research institutions including City of Hope and Nationwide Children's Hospital and is advancing two main product candidates: MB-101, an IL13Rα2-targeted CAR T cell therapy, and MB-108, an HSV-1 oncolytic virus therapy, with a planned combination study (MB-109) potentially initiating in the second quarter of 2026. The company has not generated any product revenue and has accumulated losses of $398.6 million as of December 31, 2025; it generates no revenue and is entirely dependent on raising capital to fund development. [10-K 2026-03-19]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$2.03M | −$1.98M | $15.15M | [10-Q 2026-08-05] |
| FY ended Dec 2025 | — | −$1.92M | −$5.26M | $17.27M | [10-K 2026-03-19] |
| FY ended Dec 2024 | — | −$15.75M | −$11.41M | $6.84M | [10-K 2026-03-19] |
- Quarterly cash burn
- −$987.5K
Capital structure and dilution
- Shelf registration
- S-1 filed 2025-01-15; declared effective 2025-04-11 [S-1 2025-01-15]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-04-17. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-04-17 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-04-17] |
| 2024-11-15 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-11-15] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-04-24 | Litchman Manuel Md | other | 19 | $0.75 | [4 2026-04-27] |
| 2026-01-02 | Fortress Biotech, Inc. | grant | 278,385 | — | [4 2026-01-05] |
| 2025-12-30 | Herskowitz Neil | sell | 247 | $0.96 | [4 2025-12-30] |
| 2025-12-30 | Chill Adam J. | sell | 4 | $0.95 | [4 2025-12-30] |
| 2025-12-30 | Jin David | buy | 247 | $0.96 | [4 2025-12-30] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-05 | 10-Q | Quarterly report |
| 2026-05-05 | 10-Q | Quarterly report |
| 2026-04-17 | 8-K | Listing notice or transfer |
| 2026-03-19 | 10-K | Annual report |
| 2026-01-05 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2025-12-23 | 8-K | Shareholder vote results; Other events |
| 2025-12-03 | DEF 14A | Proxy statement |
| 2025-11-07 | 10-Q | Quarterly report |
Alerts for $MBIO
Email me when Mustang BIO, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.